Biomarkers for Neuropsychiatric Syndromes and Diseases
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Physiology and Pathology".
Deadline for manuscript submissions: closed (28 July 2023) | Viewed by 490
Special Issue Editor
Special Issue Information
Dear Colleagues,
I am excited to present this new Special Issue, “Biomarkers in Neuropsychiatric Syndromes and Diseases”, hosted by Life. This collection aims to map the landscape of biomarker research using a vast array of technologies across a broad range of neuropsychiatric disorders.
The field of biomarkers research has seen considerable growth for several neurodegenerative disorders, including amyotrophic lateral sclerosis, Alzheimer’s disease, fronto-temporal dementia, and Parkinson’s disease. In contrast, biomarkers research faces ongoing challenges when it comes to major psychiatric disorders, including schizophrenia, major depression, and bipolar disorder.
This research topic collection intends to present a comprehensive survey of the state of biomarkers research. We aim to include a variety of biomarker “omics” and connectome methodologies, including genomics, proteomics, metabolomics, metagenomics, phenomics and transcriptomics, applied across a range of neuropsychiatric disorders, from “harder” neurological diseases such as Parkinson’s disease through mid-way neuropathologies such as Alzheimer’s dementia to “softer” neuropsychiatric syndromes such as schizophrenia.
We welcome reviews, systematic reviews, and original research manuscripts addressing topics including, but not limited to, the following:
- Attempts to demonstrate the benefits of a biomarker-driven approaches in neuropsychiatric diagnosis, including personalized medicine;
- Attempts to demonstrate the benefits a biomarker-driven approach to neuropsychiatric treatments, including person-centered care;
- Attempts to validate current biomarker-driven approaches to the diagnosis and treatment of neuropsychiatric disorders;
- Attempts to establish novel biomarkers for neuropsychiatric disorders.
Prof. Dr. Adrian Preda
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biomarkers
- genomics
- proteomics
- metabolomics
- metagenomics
- phenomics and transcriptomics
- human connectome
